Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- (-) Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 169 Results
Mallinckrodt’s Steven Romano Elected National Pharmaceutical Council Board Chair
NPC announced Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC’s Board of Directors for 2021-2022.
Health Spending for Commercial Plans Is Predominantly Concentrated In Small Population of High-Intensity Consumers
NPC study finds spending on prescription drugs mirrors spending on other health care services, with a small subset of the sickest patients driving the majority of spending.
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are…
Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective
In a commentary for Pharmacy Times, NPC's John M. O’Brien describes the commitment of pharmacists to ensuring patient access to needed medicines and says other health care stakeholders…
Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health
A Health Affairs Blog co-authored by NPC's Michael Ciarametaro explores the tradeoffs and risks associated with international reference pricing and suggests alternative policy approaches that…
Going Below The Surface
Going Below The Surface was an NPC-led initiative to broaden and improve the conversation around how we use health care resources in the United States.
NPC in Health Affairs: Payment Innovation Not Keeping Up
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…
NPC Commits to Mandating COVID-19 Vaccination
NPC joined a group of 14 health care organizations in and around Washington, D.C., in issuing a joint statement making COVID-19 vaccination a condition of returning to work in their respective…
NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
Affordability Is About More Than Drug Prices
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Celebrating the Use of Medicines in Keeping People Healthy
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
Let’s Work Together to Improve Our Health Care System
NPC's new president and CEO outlines his commitment to working with all partners, across all sectors, to improve our health care system.
The Budget Cap Dilemma: Can You Reduce Spending and Preserve Patient Health?
National Pharmaceutical Council (NPC) hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Focus on Whole Person Quality Care When Implementing Budget Caps
The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
National Pharmaceutical Council Appoints John M. O’Brien as President and CEO
Veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, has been appointed as president and chief executive officer of the National Pharmaceutical Council, effective June 1,…
U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
The American Journal of Managed Care® Adds National Pharmaceutical Council to Strategic Alliance Partnership Program
The American Journal of Managed Care® (AJMC®) and Pharmacy Times® today announced that the National Pharmaceutical Council (NPC) has joined their Strategic Alliance Partnership (SAP) programs.
Assessing Consumer and Employer Willingness to Pay for New Medical Technologies
This study examines whether health care consumers and large employers would be willing to continue to pay for new medical technologies associated with significant improvements in patient health…